Andrea Tannapfel

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

Salah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz, Claudia Pauligk et al. · The Lancet Oncology · 2016 · 739 citations

Medicine, Oncology, Pharmacology +16

Characterization of Foxp3+CD4+CD25+ and IL-10-Secreting CD4+CD25+ T Cells during Cure of Colitis

Holm H. Uhlig, Janine L. Coombes, Christian Mottet et al. · The Journal of Immunology · 2006 · 448 citations · Full text

Life Sciences, Cell Biology, Immunology +17

Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer

Emmanouil Fokas, Anke Schlenska‐Lange, Bülent Polat et al. · JAMA Oncology · 2021 · 354 citations · Full text

Medicine, Surgery, Gastrointestinal Oncology +13

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

Dominik Paul Modest, Ingrid Ricard, Volker Heinemann et al. · Annals of Oncology · 2016 · 344 citations · Full text

Medicine, Biostatistics, Oncology +17

Mutations of the <i>BRAF</i> gene in cholangiocarcinoma but not in hepatocellular carcinoma

Andrea Tannapfel · Gut · 2003 · 342 citations · Full text

Medicine, Molecular Biology, Oncology +17